We are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.
|Recent News||more >|
Kura Oncology Reports Second Quarter 2016 Financial Results
Kura Oncology to Report Second Quarter 2016 Financial Results
Kura Oncology Doses First Patient in Phase 2 Study of Tipifarnib in Lower Risk Myelodysplastic Syndromes
|Receive E-mail Alerts|
|Sign up to receive e-mail alerts whenever Kura Oncology Inc posts new information to the site. Just enter your e-mail address and click Submit.|
|Data provided by Nasdaq. Minimum 15 minutes delayed.|